Related Experiment Videos
The safety of long-term clindamycin therapy for acne
Abstract:
Sixty patients with severe pustular and cystic acne were treated for prolonged periods with clindamycin (150 mg to 300 mg daily). The average duration of therapy was five months, with 18 patients being treated for more than six months. Only two (3.4%) patients developed mild diarrhea, which was rapidly reversible on discontinuance of the drug. No other adverse reactions were observed. These data suggest that long-term, low-dose clindamycin therapy may be safe for severe pustular of cystic acne.
Insights
Long-term, low-dose clindamycin therapy is safe for severe acne. Most patients experienced no adverse reactions, with only mild, reversible diarrhea reported in a small percentage.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Severe pustular and cystic acne significantly impacts patients' quality of life.
- Current treatment options may have limitations or side effects.
Purpose of the Study:
- To evaluate the safety and tolerability of prolonged, low-dose clindamycin for severe acne.
- To assess adverse reactions associated with long-term clindamycin use in acne patients.
Main Methods:
- A cohort of sixty patients with severe pustular and cystic acne was enrolled.
- Patients received clindamycin at a dosage of 150 mg to 300 mg daily for extended periods.
- Treatment duration averaged five months, with some patients treated for over six months.
Main Results:
- Only two patients (3.4%) reported mild diarrhea, which resolved upon drug discontinuation.
- No other adverse reactions were observed during the prolonged treatment period.
- The overall safety profile of long-term clindamycin was favorable.
Conclusions:
- Prolonged, low-dose clindamycin therapy appears to be a safe treatment option for severe pustular and cystic acne.
- The observed adverse effects were minimal and transient, suggesting good tolerability.
- Further research may support clindamycin as a viable long-term management strategy for severe acne.